Theolytics appoints new Chief Medical Officer

08 October 2025

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO).

Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in patients with platinum-resistant ovarian cancer.

David Apelian, CEO of Theolytics, said, “I am thrilled to welcome Matilde as our new Chief Medical Officer. As a clinical-stage company, this is a crucial appointment for Theolytics, and I am confident that with her extensive expertise in medical oncology in all phases of clinical development, Matilde will be instrumental in driving our clinical strategy for THEO-260 and our future clinical pipeline.”

Dr Saggese is a medical oncologist, with over 20 years of experience in treating patients with solid and haematological malignancies at the Careggi University Hospital in Florence, Italy, the Royal Marsden Hospital and the Sarah Cannon Research Institute, both in London, UK.

Her research experience includes laboratory assignments at Cornell Medical Center and Memorial Sloan Kettering Cancer Center, both in New York state, and at the UCL Cancer Institute in London. Dr Saggese also brings extensive industry experience in medical affairs and clinical development from her time at AstraZeneca, and most recently as VP of Clinical Development and Interim CMO at Achilles Therapeutics, where she was responsible for the development of novel cellular immune-oncology therapies.

Dr Saggese completed a Bachelor of Medicine, Bachelor of Surgery (BMMS) at the Medical University of Pavia, Italy, followed by completion of the post-graduate School in Medical Oncology (CCT) at the Medical University of Florence, Italy and a MD (Res) at the Cancer Institute, University College of London, UK

Matilde Saggese, CMO of Theolytics, said: “I am excited to join the excellent team at Theolytics as we pursue a mission to develop innovative therapies that hold the promise of lasting cures for cancer patients. Ovarian cancer remains a disease with high unmet need, and with the differentiated profile of THEO-260, I believe we have an opportunity to make a meaningful difference for the many women suffering from this disease.”

For more information, please visit: www.theolytics.com

Read other news articles

News

Theolytics appoints new Chief Medical Officer